key: cord-1005707-vf5mnvwf
authors: Pissa, Maria; Gulin, Sandra Jerkovic
title: The incidence of melanoma during the COVID-19 pandemic in a Swedish health care region without lockdown.
date: 2021-12-24
journal: JAAD Int
DOI: 10.1016/j.jdin.2021.12.004
sha: 34bc56e20343d2bd27283c60ee1e372486c1576a
doc_id: 1005707
cord_uid: vf5mnvwf

nan

The incidence of melanoma during the COVID-19 pandemic in a Swedish health care region 30 without lockdown. 31 COVID-19 was declared a pandemic in March 2020 [1, 2] . The first case of SARS-CoV-2 in Sweden 33 was confirmed on January 24, 2020, at Ryhov County Hospital in Jonkoping. Delayed melanoma 34 diagnosis strongly influences patients' survival [3] . Several studies have reported the impact of the 35 COVID-19 pandemic on skin cancer incidence [4] . According to a study from England melanoma 36 incidence has decreased compared to the incidence of all types of cancer overall (excluding non-37 melanoma skin cancers) [5] . Therefore, this study aimed to test the hypothesis that the number of newly 38 diagnosed hospital melanoma cases decreased during the COVID-19 pandemic due to reduced access 39 to specialist care. 40

A retrospective, observational cohort study has been done in the three hospitals (Ryhov County hospital, 41

Highland hospital of Nassjo, and Varnamo hospital) in Region Jonkoping County, which is part of the 42 southeast healthcare region in Sweden whose population is approximately 360 000. 43

We reviewed records from these three hospitals to identify newly diagnosed melanoma cases during the 44 COVID-19 pandemic (April 1, 2020 -March 31, 2021). Data was compared to the respective numbers 45 from the reference non-pandemic period (April 1, 2019 -March 31, 2020). The data was extracted on patients reported with a melanoma diagnosis during the COVID-19 pandemic or reference period were 48 included in the study. The study was a quality review study approved by the operations manager and 49

to Section 31 of the Health and Medical Services Act, which has been published in Lakartidningen 2015; 51 situ (stage 0) and invasive melanoma (stage I-IV) under a 24-month period. 63 melanoma in-situ cases 54 and 63 invasive melanoma cases were reported during the non-pandemic period. 67 melanoma in-situ 55 cases and 51 invasive melanoma cases were reported during the pandemic period (Figure 1) . 56 We observed a slight decrease in the number of newly diagnosed invasive melanoma cases during the 60 pandemic, compared to the non-pandemic period (the diagnoses decreased by 19%, p = 0.2620). A slight 61 increase in the number of melanoma in situ cases is observed during the pandemic, compared to the non-62 pandemic period (the diagnoses increased by 6%, p = 0.726). 63

Interestingly, the statistically nonsignificant results lead us to the conclusion that in Region Jonkoping 64

County in Sweden number of newly diagnosed melanoma cases (both melanoma in situ and invasive 65 melanoma) remained approximately unchanged during the pandemic period compared to the non-66 pandemic period. Our data is in contrast to previously published one from other countries probably due 67 to mild restrictions and guaranteed access to specialist care in case of melanoma suspicion. 68 J o u r n a l P r e -p r o o f

Clinical features of patients infected with

General's opening remarks at the media briefing on COVID-19

Unknown primary melanoma: worldwide survey on clinical 75 management

The magnitude of COVID-19's effect on the timely 77 management of melanoma and nonmelanoma skin cancers

The impact of the COVID-19 pandemic on skin cancer 80 incidence and treatment in England, 2020